Parinaz Aliahmad

Dr. Parinaz Aliahmad

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CMChristian J. Maine
Christian J. Maine
SMShigeki J. Miyake-Stoner
Shigeki J. Miyake-Stoner
DSDarina S. Spasova
Darina S. Spasova
GPGaelle Picarda
Gaelle Picarda
ACAnnie C. Chou
Annie C. Chou
PAParinaz Aliahmad
Parinaz Aliahmad
Self-replicating RNA (srRNA) technology, in comparison to mRNA vaccines, has shown dose-sparing by approximately 10-fold and more durable immune responses. However, no improvements are observed in the adverse events profile. Here, we develop an srRNA vaccine platform with optimized non-coding regions and demonstrate immunogenicity and safety in preclinical and clinical development. Optimized srRNA vaccines generate protective immunity (according to the WHO defined thresholds) at doses up to 1,000,000-fold lower than mRNA in female mouse models of influenza and rabies. Clinically, safety and immunogenicity of RBI-4000, an srRNA vector encoding the rabies glycoprotein, was evaluated in a Phase I study (NCT06048770). RBI-4000 was able to elicit de novo protective immunity in the majority of healthy participants when administered at a dose of 0.1, 1, or 10 microgram (71%, 94%, 100%, respectively) in a prime-boost schedule. Similarly, we observe immunity above the WHO benchmark of protection following a single administration in most participants at both 1 and 10 microgram doses. There are no serious adverse events reported across all cohorts. These data establish the high therapeutic index of optimized srRNA vectors, demonstrating feasibility of both low dose and single dose approaches for vaccine applications.

22 February 2022 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
PAParinaz Aliahmad
Parinaz Aliahmad
SMShigeki J. Miyake-Stoner
Shigeki J. Miyake-Stoner
AGAndrew J. Geall
Andrew J. Geall
NWNathaniel S. Wang
Nathaniel S. Wang
RNA technology has recently come to the forefront of innovative medicines and is being explored for a wide range of therapies, including prophylactic and therapeutic vaccines, biotherapeutic protein expression and gene therapy. In addition to conventional mRNA platforms now approved for prophylactic SARS-CoV2 vaccines, synthetic self-replicating RNA vaccines are currently being evaluated in the clinic for infectious disease and oncology. The prototypical srRNA vectors in clinical development are derived from alphaviruses, specifically Venezuelan Equine Encephalitis Virus (VEEV). While non-VEEV alphaviral strains have been explored as single cycle viral particles, their use as synthetic vectors largely remains under-utilized in clinical applications. Here we describe the potential commonalities and differences in synthetic alphaviral srRNA vectors in host cell interactions, immunogenicity, cellular delivery, and cargo expression. Thus, unlike the current thinking that VEEV-based srRNA is a one-size-fits-all platform, we argue that a new drug development approach leveraging panels of customizable, synthetic srRNA vectors will be required for clinical success.

25 March 2026 in Molecular Therapy
Verified
Journal Article
Open access
SMShigeki J. Miyake-Stoner
Shigeki J. Miyake-Stoner
CMChristian J. Maine
Christian J. Maine
ACAnnie C. Chou
Annie C. Chou
GDGabrielle P. Dailey
Gabrielle P. Dailey
DSDarina S. Spasova
Darina S. Spasova
PAParinaz Aliahmad
Parinaz Aliahmad
Self-replicating RNA (srRNA) technology has received its first approval with Kostaive and EUA for GEMCOVAC COVID-19 vaccines. The effective doses for srRNA vaccines are far lower than for conventional mRNA, as srRNA drives greater protein expression and has attributes of viral vectors that can potentiate immunogenicity. Importantly, srRNA encodes for a viral replicase, frequently derived from non-structural proteins (nsP) from Venezuelan equine encephalitis virus (VEEV), that helps amplify the encoded transgene. nsPs also influence critical cellular processes, including protein translation and processing, inflammation and autophagy, that can impact downstream performance. Here we show that a next-generation srRNA vector derived from Eastern equine encephalitis virus (EEEV), identified from a wider screen of alphaviruses, that has high potency in two immunotherapeutic applications, RBI-1000 and RBI-2000. RBI-1000, a multigenic vaccine targeting acquired resistance mutations in breast cancer, was able to elicit antigen-specific immune responses to tumor-associated antigens and neoantigens. In addition, RBI-2000, a combination IL-12 and IL-1RA biotherapeutic, resulted in therapeutic levels of protein expression that bolstered anti-tumor immune responses in vivo. Both RBI-1000 and RBI-2000 successfully demonstrated efficacy in preclinical tumor models. These data show the importance of empirically evaluating new srRNA vectors for the development of fit-for-purpose therapies.